Biopharma · FDA Approvals · Stock

GALT Galectin Therapeutics

Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse…

Assets on file: belapectin

Start live analysis of GALT Run 8-agent AI analysis Stock overview All sector events →

Catalyst calendar

Dated catalysts for GALT, including recently decided ones.

Nothing scheduled in this window.

Recent first-hand events

Every first-hand event for GALT, newest first.

Instant stream — events appear as soon as they are filed.

Material

Jun 23, 2026

12:00 PM

GALTGalectin Therapeutics

Galectin Therapeutics: FDA aligns on Phase 3 belapectin design

FDA agreed on the Phase 3 primary endpoint (composite liver outcome including large esophageal varices) and full-approval regulatory path for belapectin in MASH cirrhosis with portal hypertension. The company will submit the final Phase 3 protocol in Q3 2026 and is seeking strategic/financial partners.

Trial registry changeCompany press release Open record

Notable

Nov 10, 2025

12:56 PM

GALTGalectin Therapeutics

GALT presents NAVIGATE trial biomarker data at AASLD 2025

The company presented new biomarker analyses from the Phase 2 NAVIGATE trial at the AASLD 2025 meeting. Belapectin 2 mg/kg showed consistent antifibrotic effects across ELF, Pro-C3, YKL-40, and PRO-C4 biomarkers, with sustained reduction in new varices through 36 months. These data reinforce the drug's disease-modifying potential in compensated MASH cirrhosis with portal hypertension.

Conference presentationSEC 8-K